[Clinical value of the early use of ulinastatin in patients with moderately severe or severe acute pancreatitis].

作者：J Wang, Jong‐Youl Jin, Jing Huang, D R Li, Ying-Xia Hao, Jian Kong, Zachary Chu, J H Fu, Feng Huang · 发表于：PubMed · 年份：2017 · DOI：10.3760/cma.j.issn.0376-2491.2017.16.015 · 被引用次数：8 · 研究领域：Pancreatitis Pathology and Treatment、Biomarkers in Disease Mechanisms

The early use of ulinastatin in the patients with MSAP/SAP can down-regulated the levels of TNF-α, IL-6 and IL-8, reduce the inflammatory response, decrease intra-abdominal pressure and shorten abdominal pain time. It was beneficial and worthy of wider popularization.